Small-molecule agents for the treatment of inflammatory bowel disease

  • Bioorg Med Chem Lett. 2019 Aug 15;29(16):2034-2041. doi: 10.1016/j.bmcl.2019.06.042.
Kevin S Currie  1 ,  Leena Patel  2 ,  Kassandra F Sedillo  2
Affiliations
  • 1. Gilead Sciences, 199 East Blaine St., Seattle, WA 98102, United States. Electronic address: [email protected].
  • 2. Gilead Sciences, 199 East Blaine St., Seattle, WA 98102, United States.
PMID: 31266686 DOI: 10.1016/j.bmcl.2019.06.042
Abstract

Inflammatory bowel disease (IBD) is a chronic, debilitating condition with a significant impact on quality of life. In spite of recent advances with antibody therapies, there remains a significant unmet medical need in IBD. Ongoing research and development efforts aim to identify new therapies that will increase remission rates beyond those achieved with current standard-of-care, while maintaining a high safety margin. This review will provide an overview of the small-molecule agents that are being explored in this regard.

Keywords
Crohn’s disease; Inflammatory bowel disease; Small-molecule; Ulcerative colitis.
Products